The passage of the Consolidated Appropriations Act (CAA) of 2026 represents one of the most significant federal moves toward pharmacy benefit manager (PBM) transparency in recent years. For employers, brokers, HR leaders, and executive teams who have struggled to understand the true drivers behind rising pharmacy spend, the legislation reinforces a growing industry consensus: Transparency…
The prescription drug cost crisis in the United States has escalated from an individual financial strain into a systemic workforce and corporate liability. According to tracking data from KFF (Kaiser Family Foundation), roughly 43% of U.S. adults report not taking their medications as prescribed over the past year due to cost. This isn’t just about…
The enactment of the Consolidated Appropriations Act (CAA) of 2026 marks a significant step toward greater transparency and accountability in the pharmacy benefit management (PBM) industry. For employers, brokers, HR leaders, and executive teams that have struggled to understand the true drivers behind rising pharmacy spend, the legislation sends a clear signal: greater transparency is becoming…
Prescription drug costs continue to climb, and the spotlight is once again turning toward one of healthcare’s most influential, yet least understood, players: pharmacy benefit managers (PBMs). This week, Congress announced plans to advance legislation aimed at increasing oversight of PBMs and addressing concerns around transparency, pricing practices, and the role these organizations play in…
The pharmaceutical landscape is currently approaching a seismic shift known as the “patent cliff.” For years, a handful of blockbuster specialty medications have dominated healthcare budgets, protected by a fortress of intellectual property. As these patents expire, the market is poised for an influx of competition that promises to redefine how plan sponsors manage their…
The landscape of pharmacy benefits is currently being reshaped by a new generation of medicine. For years, specialty spend has been dominated by biologics—complex, high-cost medications derived from living organisms. While these drugs have revolutionized the treatment of chronic conditions, they have also become the primary driver of unsustainable health plan costs. The solution lies…
In the complex ecosystem of pharmacy benefits, the “rebate wall” is one of the most significant obstacles to achieving true expense optimization. While the term may sound like a financial safeguard, it is actually a strategic hurdle used by drug manufacturers and Pharmacy Benefit Managers (PBMs) to protect high-cost, brand-name medications from lower-priced competition. For…
For decades, the pharmacy benefit industry has operated behind a curtain of complexity that serves the intermediary far more than the employer. We are currently navigating a marketplace where traditional Pharmacy Benefit Managers (PBMs) utilize intricate, proprietary ecosystems to generate significant revenue through methods that never appear on a line item. For plan sponsors, these…
For years, the pharmacy benefit industry has operated under a veil of complexity that makes it difficult for employers and brokers to determine if they are getting a fair deal. At the heart of this confusion are two competing financial models: Spread Pricing and Cost-Plus Pricing. While one relies on hidden margins and misaligned incentives,…
While it is easy to dismiss these terms as industry jargon, the specific benchmark used in a contract determines how much “invisible” profit a PBM can rake in. When a broker moves a client from an AWP-based contract to a more transparent model, they are essentially pulling back the curtain on traditional PBM’s profit centers….